{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:58:46Z","timestamp":1790182726643,"version":"4.1.0"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T00:00:00Z","timestamp":1246406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2009,7]]},"DOI":"10.1016\/j.ejim.2009.05.012","type":"journal-article","created":{"date-parts":[[2009,6,22]],"date-time":"2009-06-22T09:36:16Z","timestamp":1245663376000},"page":"S303-S308","source":"Crossref","is-referenced-by-count":44,"special_numbering":"S2","title":["Unraveling the Science of Incretin Biology"],"prefix":"10.1016","volume":"20","author":[{"given":"Michael A.","family":"Nauck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2009.05.012_bib1","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1161\/CIRCULATIONAHA.106.613828","article-title":"Trends in the incidence of type 2 diabetes mellitus from the 1970s to the 1990s","volume":"113","author":"Fox","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2009.05.012_bib2","series-title":"Centers for Disease Control National Diabetes Fact Sheet","year":"2007"},{"key":"10.1016\/j.ejim.2009.05.012_bib3","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2337\/diacare.26.1.61","article-title":"Age- and sex-specific prevalences of diabetes and impaired glucose regulation in 13 European cohorts","volume":"26","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejim.2009.05.012_bib5","first-page":"88","article-title":"Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary","volume":"28","author":"Ryd\u00e9n","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2009.05.012_bib8","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(06)68967-8","article-title":"Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study","volume":"368","author":"Booth","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2009.05.012_bib9","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.2337\/dc06-9912","article-title":"Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy","volume":"29","author":"Nathan","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejim.2009.05.012_bib10","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.2337\/diabetes.44.11.1249","article-title":"U.K. Prospective Diabetes Study 16: overview of 6 years' therapy of type II diabetes: a progressive disease","volume":"44","year":"1995","journal-title":"Diabetes"},{"issue":"suppl 3","key":"10.1016\/j.ejim.2009.05.012_bib11","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1463-1326.2008.00919.x","article-title":"Glucagon-like peptide-1 in type 2 diabetes: the beta cell and beyond","volume":"10","author":"Nauck","year":"2008","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ejim.2009.05.012_bib12","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1001\/archinte.168.8.820","article-title":"Use of thiazolidinediones and fracture risk","volume":"168","author":"Meier","year":"2008","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ejim.2009.05.012_bib13","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.2165\/00002018-200730120-00005","article-title":"Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus","volume":"30","author":"Hermansen","year":"2007","journal-title":"Drug Saf"},{"key":"10.1016\/j.ejim.2009.05.012_bib14","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2165\/00002018-199411040-00002","article-title":"Comparative tolerability profiles of oral antidiabetic agents","volume":"11","author":"Krentz","year":"1994","journal-title":"Drug Saf"},{"issue":"1","key":"10.1016\/j.ejim.2009.05.012_bib15","article-title":"Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus","author":"Salpeter","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ejim.2009.05.012_bib16","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.2337\/dc08-1171","article-title":"Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis","volume":"31","author":"Bodmer","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejim.2009.05.012_bib17","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3132\/dvdr.2008.002","article-title":"The importance of treating cardiometabolic risk factors in patients with type 2 diabetes","volume":"5","author":"Barnett","year":"2008","journal-title":"Diab Vasc Dis Res"},{"key":"10.1016\/j.ejim.2009.05.012_bib18","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.2337\/diacare.27.6.1496","article-title":"Lipids and lipoproteins in patients with type 2 diabetes","volume":"27","author":"Krauss","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejim.2009.05.012_bib19","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1530\/EJE-07-0804","article-title":"Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitis: glucagon-like agonists or insulin for patients with inadequate glycemic control","volume":"158","author":"Van Gaal","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ejim.2009.05.012_bib20","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s001250100580","article-title":"The role of impaired early insulin secretion in the pathogenesis of type II diabetes mellitus","volume":"44","author":"Pratley","year":"2001","journal-title":"Diabetologia"},{"key":"10.1016\/j.ejim.2009.05.012_bib21","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1210\/10.1210\/er.2006-0038","article-title":"\u03b2-Cell failure in diabetes and preservation by clinical treatment","volume":"28","author":"Wajchenberg","year":"2007","journal-title":"Endocr Rev"},{"key":"10.1016\/j.ejim.2009.05.012_bib22","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2337\/diabetes.52.1.102","article-title":"Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes","volume":"51","author":"Butler","year":"2003","journal-title":"Diabetes"},{"key":"10.1016\/j.ejim.2009.05.012_bib23","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2009.05.012_bib24","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.mcna.2004.04.013","article-title":"Pathogenesis of type 2 diabetes mellitus","volume":"88","author":"DeFronzo","year":"2004","journal-title":"Med Clin North Am"},{"key":"10.1016\/j.ejim.2009.05.012_bib25","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.2337\/diabetes.55.04.06.db05-1100","article-title":"The natural course of beta-cell function in nondiabetic and diabetic individuals: the Insulin Resistance Atherosclerosis Study","volume":"55","author":"Festa","year":"2006","journal-title":"Diabetes"},{"key":"10.1016\/j.ejim.2009.05.012_bib26","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.annepidem.2007.10.007","article-title":"Prevalence, treatment, and control of diagnosed diabetes in the U.S. National Health and Nutrition Examination Survey 1999-2004","volume":"18","author":"Ong","year":"2008","journal-title":"Ann Epidemiol"},{"key":"10.1016\/j.ejim.2009.05.012_bib27","doi-asserted-by":"crossref","first-page":"625","DOI":"10.4158\/EP.14.5.625","article-title":"Can newer therapies delay the progression of type 2 diabetes mellitus?","volume":"14","author":"Horton","year":"2008","journal-title":"Endocr Pract"},{"key":"10.1016\/j.ejim.2009.05.012_bib28","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa066224","article-title":"Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy","volume":"355","author":"Kahn","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2009.05.012_bib29","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMe068264","article-title":"Thiazolidinediones for initial treatment of type 2 diabetes?","volume":"355","author":"Nathan","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2009.05.012_bib30","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/BF02427280","article-title":"Reduced incretin effect in type 2 (non-insulin-dependent) diabetes","volume":"29","author":"Nauck","year":"1986","journal-title":"Diabetologia"},{"key":"10.1016\/j.ejim.2009.05.012_bib31","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","article-title":"Biology of incretins: GLP-1 and GIP","volume":"132","author":"Baggio","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2009.05.012_bib32","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.2337\/diacare.26.10.2929","article-title":"Enhancing incretin action for the treatment of type 2 diabetes","volume":"26","author":"Drucker","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejim.2009.05.012_bib33","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes","volume":"368","author":"Drucker","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2009.05.012_bib34","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1210\/jc.76.4.912","article-title":"Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations","volume":"76","author":"Nauck","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejim.2009.05.012_bib35","doi-asserted-by":"crossref","first-page":"4897","DOI":"10.1210\/jc.2003-030738","article-title":"The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide regardless of etiology and phenotype","volume":"88","author":"Vilsb\u00f8ll","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejim.2009.05.012_bib36","doi-asserted-by":"crossref","first-page":"E621","DOI":"10.1152\/ajpendo.00499.2003","article-title":"Gastric inhibitory polypeptide does not inhibit gastric emptying in humans","volume":"286","author":"Meier","year":"2004","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.ejim.2009.05.012_bib37","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1172\/JCI116186","article-title":"Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus","volume":"9","author":"Nauck","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ejim.2009.05.012_bib38","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s00125-002-0878-6","article-title":"Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients","volume":"45","author":"Vilsb\u00f8ll","year":"2002","journal-title":"Diabetologia"},{"issue":"suppl 3","key":"10.1016\/j.ejim.2009.05.012_bib39","doi-asserted-by":"crossref","first-page":"S190","DOI":"10.2337\/diabetes.53.suppl_3.S190","article-title":"Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes","volume":"53","author":"Nauck","year":"2004","journal-title":"Diabetes"},{"issue":"suppl 3","key":"10.1016\/j.ejim.2009.05.012_bib40","doi-asserted-by":"crossref","first-page":"S220","DOI":"10.2337\/diabetes.53.suppl_3.S220","article-title":"Stimulation of insulin secretion by intravenous bolus injection and continuous infusion of gastric inhibitory polypeptide in patients with type 2 diabetes and healthy control subjects","volume":"53","author":"Meier","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.ejim.2009.05.012_bib41","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1365-2362.1992.tb01464.x","article-title":"Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man","volume":"22","author":"Eissele","year":"1992","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.ejim.2009.05.012_bib42","doi-asserted-by":"crossref","first-page":"535","DOI":"10.2337\/diabetes.43.4.535","article-title":"Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans","volume":"43","author":"Orskov","year":"1994","journal-title":"Diabetes"},{"key":"10.1016\/j.ejim.2009.05.012_bib43","doi-asserted-by":"crossref","first-page":"124","DOI":"10.2337\/diabetes.52.1.124","article-title":"Glucagon-like peptide 1 induces pancreatic \u03b2-cell proliferation via transactivation of the epidermal growth factor receptor","volume":"52","author":"Buteau","year":"2003","journal-title":"Diabetes"},{"key":"10.1016\/j.ejim.2009.05.012_bib44","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1007\/s00125-004-1379-6","article-title":"Glucagon-like peptide-1 prevents beta cell glucolipotoxicity","volume":"47","author":"Buteau","year":"2004","journal-title":"Diabetolgia"},{"key":"10.1016\/j.ejim.2009.05.012_bib45","first-page":"E981","article-title":"Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans","volume":"273","author":"Nauck","year":"1997","journal-title":"Am J Physiol"},{"key":"10.1016\/j.ejim.2009.05.012_bib46","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1210\/jc.2003-030049","article-title":"Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes","volume":"88","author":"Meier","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejim.2009.05.012_bib47","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0167-0115(94)90136-8","article-title":"The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects","volume":"51","author":"Elahi","year":"1994","journal-title":"Regulatory Peptides"},{"key":"10.1016\/j.ejim.2009.05.012_bib48","doi-asserted-by":"crossref","first-page":"791","DOI":"10.2337\/diacare.26.3.791","article-title":"Differential effects of acute and extended infusions of glucagon-like peptide-1 on first- and second-phase insulin secretion in diabetic and nondiabetic humans","volume":"26","author":"Quddusi","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejim.2009.05.012_bib49","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.2337\/diabetes.47.8.1259","article-title":"Glucagon-like peptide 1 improves the ability of the \u03b2-cell to sense and respond to glucose in subjects with impaired glucose tolerance","volume":"47","author":"Byrne","year":"1998","journal-title":"Diabetes"},{"key":"10.1016\/j.ejim.2009.05.012_bib50","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.2337\/diabetes.48.12.2358","article-title":"Glucagon-like peptide 1 and exendin 4 convert pancreatic AR42J cells into glucagon and insulin-producing cells","volume":"48","author":"Zhou","year":"1999","journal-title":"Diabetes"},{"key":"10.1016\/j.ejim.2009.05.012_bib51","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1210\/en.143.8.3152","article-title":"Insulinotropic hormone glucagon-like peptide-1 differentiation of human pancreatic islet-derived progenitor cells into insulin-producing cells","volume":"143","author":"Abraham","year":"2002","journal-title":"Endocrinology"},{"key":"10.1016\/j.ejim.2009.05.012_bib52","doi-asserted-by":"crossref","first-page":"5149","DOI":"10.1210\/en.2003-0323","article-title":"Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets","volume":"144","author":"Farilla","year":"2003","journal-title":"Endocrinology"},{"key":"10.1016\/j.ejim.2009.05.012_bib53","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0140-6736(08)61246-5","article-title":"Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial","volume":"373","author":"Garber","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2009.05.012_bib54","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1210\/jc.81.1.327","article-title":"Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients","volume":"81","author":"Willms","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejim.2009.05.012_bib55","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.2337\/diabetes.54.7.2212","article-title":"Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects","volume":"54","author":"Meier","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.ejim.2009.05.012_bib56","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/sj.ijo.0800818","article-title":"Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men","volume":"23","author":"N\u00e4slund","year":"1999","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.1016\/j.ejim.2009.05.012_bib57","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0140-6736(02)07952-7","article-title":"Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and \u00df-cell function in type 2 diabetes: a parallel-group study","volume":"359","author":"Zander","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2009.05.012_bib58","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1210\/jc.87.3.1239","article-title":"Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers","volume":"87","author":"Nauck","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejim.2009.05.012_bib59","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1055\/s-2001-12428","article-title":"Effect of GLP-1 on lipid metabolism in human adipocytes","volume":"33","author":"Villanueva-Pe\u00f1acarrillo","year":"2001","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.ejim.2009.05.012_bib60","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1172\/JCI25764","article-title":"Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage","volume":"115","author":"Knauf","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ejim.2009.05.012_bib61","doi-asserted-by":"crossref","first-page":"146","DOI":"10.2337\/diabetes.54.1.146","article-title":"Glucagon-like peptide 1 can directly protect the heart against ischemia\/reperfusion injury","volume":"54","author":"Bose","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.ejim.2009.05.012_bib62","doi-asserted-by":"crossref","first-page":"E1209","DOI":"10.1152\/ajpendo.00237.2004","article-title":"Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease","volume":"287","author":"Nystr\u00f6m","year":"2004","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.ejim.2009.05.012_bib63","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1210\/jc.2003-031403","article-title":"Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men","volume":"89","author":"Gutzwiller","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejim.2009.05.012_bib64","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1097\/00004872-200306000-00012","article-title":"Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats","volume":"21","author":"Yu","year":"2003","journal-title":"J Hypertens"},{"issue":"suppl","key":"10.1016\/j.ejim.2009.05.012_bib65","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.amjmed.2009.03.014","article-title":"Incretin therapies: effects beyond glycemic control","volume":"122","author":"Mudaliar","year":"2009","journal-title":"Am J Med"},{"key":"10.1016\/j.ejim.2009.05.012_bib66","doi-asserted-by":"crossref","first-page":"609","DOI":"10.2337\/diabetes.50.3.609","article-title":"Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients","volume":"50","author":"Vilsb\u00f8ll","year":"2001","journal-title":"Diabetes"},{"key":"10.1016\/j.ejim.2009.05.012_bib67","doi-asserted-by":"crossref","first-page":"678","DOI":"10.2337\/db07-1124","article-title":"Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance","volume":"57","author":"Vollmer","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.ejim.2009.05.012_bib68","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.2337\/db06-1033","article-title":"Downregulation of GLP-1 and GIP receptor expression by hyperglycemia: possible contribution to impaired incretin effects in diabetes","volume":"56","author":"Xu","year":"2007","journal-title":"Diabetes"},{"key":"10.1016\/j.ejim.2009.05.012_bib69","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.2337\/diacare.22.7.1137","article-title":"Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients","volume":"22","author":"Toft-Nielsen","year":"1999","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejim.2009.05.012_bib70","doi-asserted-by":"crossref","first-page":"4612","DOI":"10.1210\/jc.2006-1009","article-title":"Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes","volume":"91","author":"Herman","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejim.2009.05.012_bib71","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1111\/j.1464-5491.2007.02191.x","article-title":"Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naive patients with Type 2 diabetes","volume":"24","author":"Schweizer","year":"2007","journal-title":"Diabet Med"},{"key":"10.1016\/j.ejim.2009.05.012_bib72","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1078\/0171-9335-00302","article-title":"The multifunctional or moonlighting protein CD26\/DPPIV","volume":"82","author":"Boonacker","year":"2003","journal-title":"Eur J Cell Biol"},{"key":"10.1016\/j.ejim.2009.05.012_bib73","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.clinthera.2008.08.006","article-title":"Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study","volume":"30","author":"Moretto","year":"2008","journal-title":"Clin Ther"},{"key":"10.1016\/j.ejim.2009.05.012_bib74","series-title":"Byetta (exenatide injection) [package insert]","year":"2008"},{"issue":"suppl","key":"10.1016\/j.ejim.2009.05.012_bib75","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/j.amjmed.2009.03.013","article-title":"Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus","volume":"122","author":"Gilbert","year":"2009","journal-title":"Am J Med"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620509000958?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620509000958?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,18]],"date-time":"2018-12-18T22:23:33Z","timestamp":1545171813000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620509000958"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7]]},"references-count":72,"alternative-id":["S0953620509000958"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2009.05.012","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2009,7]]}}}